Ironwood lifts 2026 guidance again as LINZESS profit share and lower SG&A widen margins

The quarter in numbers

Ironwood reported third-quarter 2026 total revenue of $133.0 million, against $122.1 million a year earlier. GAAP net income was $59.8 million, or $0.36 per share basic and diluted, compared with $40.1 million, or $0.25 basic and $0.23 diluted, in Q3 2025. Non-GAAP net income was $60.0 million ($0.36 per share), up from $41.9 million.

Adjusted EBITDA was $97.9 million versus $81.8 million, a figure the company described as a record. Revenue grew by roughly 9% by our arithmetic, while GAAP net income rose by about half, so most of the gain came from the cost line rather than the top line.

LINZESS: demand up, price a drag in the quarter

Ironwood's revenue is almost entirely its share of LINZESS profits. U.S. LINZESS net sales, reported to Ironwood by partner AbbVie, were $324.9 million, up 3.2% from $314.9 million. Prescription demand was 63.4 million capsules, up 4.9% per IQVIA.

The company said Q3 growth reflected 4.9% demand growth offset by a low-single-digit net price decline, driven by unfavorable gross-to-net rebate reserves in Q3 2026 relative to 2025. That sits awkwardly with the company's full-year framing, which credits improved net price and mid-single-digit demand growth. The release does not quantify the gap, but the quarter shows that year-over-year price gains are not uniform.

Year-to-date U.S. net sales reached $880 million, which the company said already exceeds full-year 2025 U.S. net sales. CEO Tom McCourt said LINZESS is on its way to returning to blockbuster status for 2026.

Profit share and cost structure

Ironwood and AbbVie share U.S. brand collaboration profits equally. LINZESS commercial margin was 79.8%, against 75.9% a year earlier. Net profit for the brand collaboration, after commercial and R&D expenses, was $255.9 million, up 9.8% from $233.1 million. Collaboration revenue to Ironwood was $129.9 million, up 8.6% from $119.6 million. Royalties and other revenue added $3.1 million, versus $2.5 million.

Total costs and expenses fell to $39.9 million from $46.6 million. R&D rose to $28.3 million from $22.5 million, but SG&A dropped to $11.6 million from $21.9 million, and the prior-year quarter carried $2.2 million of restructuring expense. Interest expense declined to $6.2 million from $8.4 million; the company said this year's charge relates to its revolving credit facility, while last year's also included convertible senior notes. Income tax expense was essentially flat at $27.8 million versus $27.9 million, most of it non-cash as the company continues to use net operating losses and tax credits.

Cash flow, balance sheet and guidance

Operating cash flow was $130.8 million, versus $47.6 million in Q3 2025. Ironwood repaid $60.0 million on its revolving credit facility, leaving $325.0 million outstanding at September 30, 2026, with $225.0 million of remaining capacity. Cash and equivalents were $86.4 million, down from $215.5 million at the end of 2025. The release excerpt does not detail the drivers of that nine-month decline. Accounts receivable were $132.7 million, mainly Q3 collaboration revenue.

Guidance was raised for the second consecutive quarter. U.S. LINZESS net sales are now expected at $1.20-$1.25 billion (previously $1.15-$1.20 billion), which the company said represents an increase of more than 35% year over year. Total revenue guidance moved to $485-$510 million from $460-$485 million. Adjusted EBITDA is now expected to exceed $350 million, up from more than $310 million. The company assumes no material business development expenses in 2026.

Simple arithmetic on the $880 million year-to-date figure implies Q4 LINZESS net sales of roughly $320-$370 million, compared with $325 million in Q3. The low end therefore implies a modest step down from Q3.

Pipeline, leadership and what to watch

The main pipeline item is apraglutide, a once-weekly GLP-2 analog. The confirmatory Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure is a global, 24-week, randomized, double-blind, placebo-controlled study. Its primary endpoint is the relative change from baseline in actual weekly parenteral support volume at week 24. The company said activation of more than 100 sites in 22 countries is on track, and that all planned clinical trial applications to international authorities have been submitted and are under review or approved. Subject to the trial results, Ironwood plans to file for regulatory approval in 2029 and aims to identify ways to accelerate the program.

Separately, Chief Commercial Officer Tammi Gaskins becomes CEO on January 1, 2027, when Tom McCourt retires from the role and stays on the board.

Watch for the Q4 gross-to-net trajectory against the full-year net price narrative, site activation pace in STARS-2, how R&D spending evolves as the trial ramps, and further debt paydown against the lower cash balance.